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A B S T R A C T
Last years, more than 46 unique biosimilars were approved by EMA and/or US-FDA following patent expiration
of reference products. Biosimilars are not identical like generics, but highly similar versions where demon-
strating biosimilarity of quality attributes (QAs) to a reference product is the basis of development and reg-
ulatory approval. Information on QAs assessed to establish biosimilarity may not always be publicly available,
although this information is imperative to understand better the science behind biosimilars approval. This study
aims to identify QA types reported in publications presenting biosimilarity assessments of (intended) biosimilars
over time. English full-text publications presenting biosimilarity assessments of QAs for (intended) biosimilars
between 2000 and 2019 identified from PubMed and EMBASE. Publication characteristics and QAs classified
into: structural (physicochemical properties, primary structure, higher-order structures (HOSs), post-transla-
tional modifications (PTMs), and purity and impurities) and functional (biological and immunochemical ac-
tivities) were extracted from publications. Seventy-nine publications were identified (79% open-access, 75%
industry-sponsored, 62% including unapproved biosimilars, and 66% involving antibodies). Reporting fre-
quencies varied for QA types: biological activity (94%), physicochemical properties (81%), PTMs (79%), primary
structure (77%) purity and impurities (73%), HOSs (58%), and immunochemical activity (41%). The number of
publications increased from 6 (7%) during 2009–2011 to 62 (79%) during 2015–2019. Eighteen (28%) pub-
lications reported all QA types relevant to an active-biological-substance. Reporting of most QA types increased
over time that most evidenced by immunochemical activity (from 0% to 47%) which occured after EMA
monoclonal antibody (mAbs) guidline in 2012 and more publications on mAbs later on when compared to earlier
period. Biosimilarity assessments of QAs have been published in peer-reviewed publications for about 60% of
approved biosimilars. Publishing biosimilarity assessments and reporting QAs over time appears to be affected
by regulatory actions that occurred in 2012-2015, including regulatory approval and development of regulatory
guidelines for biosimilars. Availability of a complete, publicly accessible and unbiased biosimilarity assessment
of QAs, as part of a trusted and transparent regulatory process, will contribute to increased confidence and
acceptance of biosimilars in clinical practice.
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Recombinant DNA technology has enabled the production of ther-
apeutic proteins as effective, mechanism-based treatments for a variety
of diseases (Avidor et al., 2003). Since the first recombinant human
insulin was granted regulatory approval in 1980 (Johnson, 1983),
multiple generations of recombinant DNA therapeutics ranging from
single polypeptide chains such as hormones and cytokines to substantial
and complex coagulation factors and antibodies have been developed
and have received regulatory approval (Walsh, 2000; 2003; 2006;
2010; 2014; 2018). Biologicals offer important treatment options and
accounted for 47% of all medicinal products containing novel mole-
cular (chemical or biological) entities that were approved between
2014 and July 2018 in the US (Walsh, 2018).
As patents of several biologicals have expired, the door opened for
the development of subsequent versions: the so-called biosimilars or
follow-on biologics. The first regulatory pathway for the approval of
biosimilars was developed in 2005 by the European Medicines Agency
(EMA) (EMA, 2014; EMA, 2015). Subsequently, after years of debate,
the US Food and Drug Administration (US-FDA) launched an abbre-
viated regulatory pathway for biosimilars in 2015 (US-FDA, 2015a;
2015b). These biosimilar regulations intended to enable wider and
earlier patient access for important medicines and to realize remarkable
cost savings to reduce pressure on health care budgets (McCamish and
Woollett, 2012; Aladul et al., 2017). Up to this date, no product-specific
safety and/or efficacy concerns were identified in clinical practice for
licensed biosimilars in Europe supporting the robustness of the current
regulatory framework (Vermeer et al., 2019; Cohen et al., 2018;
McKinnon et al., 2018)
In contrast to chemically synthesized generics that are identical
copies, biosimilars are highly similar versions with respect to quality
characteristics, biological and clinical activity, safety, and efficacy of
the previously authorized reference products. The comparability as-
sessment of quality attributes (QAs) between a biosimilar and the re-
ference product is the basis for establishing biosimilarity during the
development and regulatory approval of biosimilars. Quality attributes
are measurable product characteristics that describe the physical, che-
mical, biological, and microbiological properties of a drug molecule
(ICH, 2009). In contrast to chemical drugs, biologicals are large and,
often, complex molecules produced by living systems. This, and the
complexity of the molecular structure and production process for bio-
logicals results in a drug molecule with intrinsic variability (isoforms)
and subsequent variability in QAs. The QAs of biologicals are hetero-
geneous and susceptible to changes in production processes that may,
intentionally or not, for the same product result in gradual or sudden
changes over time (Vezér et al., 2016; Vulto and Jaquez, 2017). Thus,
variability in QAs of all biologicals is inevitable between batches de-
rived from the same process; even isoforms in a single batch hardly
remain constant over (storage) time (Schiestl et al., 2011; Planinc et al.,
2017; Kim et al., 2017).
Demonstrating biosimilarity requires a stepwise comparability as-
sessment between a biosimilar and a reference product. The compar-
ability of QAs is the mainstay for detecting potential differences and
establishing biosimilarity. As a result of the advancement in science and
analytical technology, the comparative efficacy (phase III) trials be-
came less important for certain product classes such as filgrastim, ter-
iparatide and insulin biosimilars (EMA, 2015; Wolff-Holz et al., 2019).
Over the last decade, more than forty-six unique biosimilars (>
eighty-seven brand names) have received regulatory approval from the
EMA and/or US-FDA and this number is expected to further increase
over the coming years. Although there is a robust and reliable reg-
ulatory framework for the approval of biosimilars, the uptake of and
trust in biosimilars in the US and some European countries is still very
low (European Commission, 2019; GaBI, 2019; Rathore et al., 2019).
Clinicians focus on clinical trial data whereas the regulatory approval of
biosimilars heavily relies on the comparability/biosimilarity assessment
of QAs. The selection of QAs needed to establish the biosimilarity is not
standardized yet and information on QAs accessible in the public do-
main is variable and for quite a few products limited. Compendial
European and US pharmacopeia monographs cannot be considered as
reference because these may not capture all QAs of the reference pro-
duct, and have not yet been developed for clinical use (Thorpe and
Wadhwa, 2011). The information on QAs of biosimilars are docu-
mented by the developers in confidential registration dossiers that are
not publicly available, and reflected by the regulators in public as-
sessment reports that are generally not well-known by stakeholders
(Hallersten et al., 2016). Sharing information on QAs through peer-
reviewed scientific publications in a transparent manner is imperative
to better understand the science behind the regulatory approval of
biosimilars. As the clinical profile of biological drugs is influenced by
their structural and functional QAs, information on QAs also results in
better understanding on the role of QAs on clinical parameters. Pre-
vious systematic reviews show that there is a substantial discordance in
the extent of published evidence to support establishing the biosimi-
larity between biological molecules across therapeutic areas[31-33].
However, no overview on the types of QAs studied in scientific pub-
lications to establish the biosimilarity is available in literature. There-
fore, this study aims to identify the types of QA reported in scientific
publications and provide an overview of the dynamics of scientific
publications presenting biosimilarity assessments of QAs for (intended)
biosimilars over time.
2. Methods
2.1. Systematic literature search
PubMed and EMBASE databases were used to collect scientific
publications in peer-reviewed journals that presented biosimilarity as-
sessments (i.e. analytical comparison) of QAs for (intended) biosimilars.
The word “intended”, hereafter, refers to any version of a recombinant
therapeutic protein that was not approved by the EMA or US-FDA as a
biosimilar at the date of publication. A search strategy was constructed
to systematically identify relevant scientific publications between
January 1, 2000 and December 31, 2019. Search strings were created to
include indexed terms and controlled keywords that were selected to
define a search domain, determinant, and outcomes. The search for-
mula (Domains AND (Determinants OR Outcomes)) was applied, which
is provided in Supplementary Table-S1a-b. Screening of titles and
abstracts was performed to verify the search strings. The search filter
title/abstract was used to retrieve publications pertinent to the study
objective. The search strings were executed on May 21, 2018 and were
refreshed on January 1, 2020 to capture recently indexed scientific
publications up to December 31, 2019. This search was conducted ac-
cording to PRISMA guidelines (Moher et al., 2009).
2.2. Inclusion criteria
Duplicate publications identified by the search strategy were re-
moved by the first author (AMA). The titles and abstracts of identified
publications were screened by the same author to identify relevant and
eligible full-text publications, which were further categorized into pri-
mary source “original publication” and secondary source “review
publication”. The list of references of each review publication was
manually checked by AMA to retrieve relevant publications that were
not captured in the electronic searches. If there was doubt about the
eligibility of a publication for inclusion, a consensus decision was
reached after discussion between AMA, TJG, and HG. Publications were
considered eligible when: (I) the full-text article was in English; (II)
(intended) biosimilars were assessed; (III) the active biological sub-
stance of the reference (comparator) was clearly defined; and (IV) a
comparability/biosimilarity assessment (i.e. analytical comparison) of
QAs between and (intended) biosimilar and the reference product was
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presented. Review publications were excluded unless original data were
presented. Publications that assessed (intended) biosimilars containing
non-recombinant proteins such as human albumin or heparin were
excluded. Publications presenting comparability assessments with the
primary aim to show assay suitability or manufacturing capability were
excluded. Conference abstracts, preclinical animal studies, and all types
of clinical trials were also excluded. European public assessment reports
(EPARs) and chemistry review reports of approved biosimilars pub-
lished by the EMA or US-FDA, respectively, were not considered in this
study.
2.3. Characteristics of included scientific publications
Baseline characteristics of each included publication were regis-
tered, namely the date of publication, the access-status of the publica-
tion, the source of funding, the regulatory-status of the (intended)
biosimilar at the date of publication, and the type of active biological
substance. The date of publication was the calendar month and year at
the time of (first online) publication, which was divided into three
periods. The three periods were selected based on the year of first
publication and time frames where relevant regulatory guidelines were
published and updated by the EMA (2012) and US-FDA (2014/2015),
and defined as 2009–2011, 2012–2014, and 2015–2019. The publica-
tion access-status was defined as open or non-open access publications.
The source of funding was categorized into an industry or academic
sponsorship. If the source of funding was not clearly stated, the in-
stitution of the corresponding author was considered as the source of
funding. The regulatory-status of the (intended) biosimilar was defined
as either approved or unapproved on the basis of the regulatory ap-
proval from at least one of the stringent regulatory authorities (SRAs) at
the date of publication, which were identified from the official websites
of the EMA [https://www.ema.europa.eu/en] and the US-FDA [https://
www.fda.gov/]. The active biological substance of the (intended) bio-
similars was classified into three types: antibodies, hormones, and
others such as clotting factors and enzymes.
2.4. Quality attributes
A classification scheme for the QA types was developed based on
information about QAs included in biosimilarity assessments as out-
lined in the EMA and US-FDA biosimilar guidelines (EMA, 2014; US-
FDA, 2015a). The constructed classification scheme was discussed with
regulators involved in the quality assessment of biosimilars at the Dutch
Medicines Evaluation Board (MEB) [https://english.cbg-meb.nl/]. The
QAs were first classified into structural or functional QAs, which in-
cluded seven types of QAs in total. The structural QAs included five
types: physicochemical properties, primary structure, higher-order
structures (HOSs), post-translational modifications (PTMs), and purity
and impurities. The PTMs were further divided into two subtypes: en-
zymatic PTMs including glycosylation and non-enzymatic PTMs. The
purity and impurities were divided into two subtypes: size and charge
variants. The functional QAs included two types: biological and im-
munochemical activities. All QA types included in the classification
scheme are relevant to recombinant therapeutic protein with the ex-
ception of the enzymatic PTMs and the immunochemical activity that
are only specific to glycoproteins and monoclonal antibodies and fusion
proteins, respectively (Box 1).
2.5. Data analysis
All reported QAs in the scientific publications were extracted, ana-
lyzed, and assessed using descriptive statistics. From each publication,
the reported QAs were identified and sorted according to the developed
classification scheme for the QA types (Box 1). The reporting fre-
quencies were calculated for each QA type and subtype, which were
stratified by the characteristics of the publication: publication date,
funding source, regulatory-status, and active biological substance(s)
type of the (intended) biosimilar(s). The median number for the re-
ported QA types in publication(s) per year was calculated to present the
dynamics of reporting QA types over time. For biosimilars that were
approved by EMA or US-FDA, the pertinent scientific publications were
identified for each unique biosimilar per the company development
code or, if not applicable, per brand names. If a biosimilar granted
approval from both agencies, the first regulatory approval date was
considered to calculate the time difference (in calendar months) be-
tween the date of publication and regulatory approval. Follow-up ended
on December 31, 2019. The statistical calculations were conducted
using IBM SPSS 25 Statistical software (SPSS Inc. Chicago, Illinois,
USA).
3. Results
3.1. Systematic literature search and characteristics of included publications
The search identified 1159 scientific publications that were poten-
tially eligible for inclusion. After removing the duplicates, a total of
1012 publications were identified, of which 933 were excluded after
title/abstract screening, most of which were conference abstracts or
publications not related to biosimilarity assessments of QAs for (in-
tended) biosimilars. This resulted in 79 full-text publications eligible for
inclusion and further analysis (Fig. 1).
The baseline characteristics of the 79 included publications
(Park et al., 2009; Skrlin et al., 2010; Sorgel et al., 2010; Brinks et al.,
2011; Maity et al., 2011; Meager et al., 2011; Tan et al., 2012;
Visser et al., 2013; Crobu et al., 2014; da Silva et al., 2014; Flores-
Ortiz et al., 2014; Halim et al., 2014; Hurst et al., 2014; Jung et al.,
2014; Rathore and Bhambure, 2014; Ryan et al., 2014; Sadeghi et al.,
2014; Escobedo-Moratilla et al., 2015; Lopez-Morales et al., 2015;
Miranda-Hernandez et al., 2015; Miranda-Hernandez et al., 2015;
Sorgel et al., 2015; Chen et al., 2016; Cho et al., 2016; Cuello et al.,
2016; Derzi et al., 2016; Halim et al., 2016; Hausberger et al., 2016;
Hofmann et al., 2016; Holzmann et al., 2016; Huang et al., 2016;
Liu et al., 2016; Mendoza-Macedo et al., 2016; Miranda-
Hernandez et al., 2016; Nupur et al., 2016; Velayudhan et al., 2016;
Zhao et al., 2016; Brokx et al., 2017; Hong et al., 2017; Lee et al., 2017;
Lim et al., 2017; Magnenat et al., 2017; Mastrangeli et al., 2017;
Miao et al., 2017; Montacir et al., 2017; Strand et al., 2017; Velasco-
Velazquez et al., 2017; Vorob'ev et al., 2017; Winstel et al., 2017;
Hassett et al., 2018; Jeong et al., 2018; Kronthaler et al., 2018;
Lee et al., 2018; Lee et al., 2018; Montacir et al., 2018; Montacir et al.,
2018; Morimoto et al., 2018; Nupur et al., 2018; Peraza et al., 2018;
Seo et al., 2018; Singh et al., 2018; Thennati et al., 2018; Beyer et al.,
2019; Lee et al., 2019; Hutterer et al., 2019; Jassem et al., 2019;
Korn et al., 2019; Kovacs et al., 2019; Lee et al., 2019; Lee et al., 2019;
Paek et al., 2019; Shekhawat et al., 2019; Kang et al., 2019; Kang et al.,
2020; Cerutti et al., 2019; An et al., 2019; Xu et al., 2019; Fazel et al.,
2019) are described in Table 1. A large proportion of the included
publications were open access (79%) and funded by the industry (75%).
Thirty of the included publications (38%) studied biosimilars that had
received regulatory approval at the date of publication. Most of the
included publications presented biosimilarity assessments for (in-
tended) biosimilars containing antibodies (66%).
3.2. Reporting of quality attributes over time
Reporting of QAs varied between publications where the biological
activity (94%) and physicochemical properties (81%) were the most
frequently reported QA types. When comparing the reporting of QA
types between publications, it was found that physicochemical prop-
erties (92% unapproved versus 63% approved), and primary structure
(86% unapproved versus 63% approved) were often reported in pub-
lications of unapproved biosimilars, whereas immunochemical activity
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(50% approved versus 35% unapproved, and 25% academia versus
46% industry) were often reported in publications of approved biosi-
milars and publications sponsored by industry. The majority of pub-
lications sponsored by industry (48 out of 59; 81%) and publications of
studied approved biosimilars (18 out of 30; 60%) included biosimi-
liarity assessment of QAs for antibodies. Sixty-five of the included
publications (82%) assessed (intended) biosimilars containing glyco-
proteins, for which enzymatic PTMs (e.g., glycosylation) are of re-
levance. In these 65 publications enzymatic PTMs were reported in
78%. The enzymatic PTMs were more often reported in publications of
(intended) biosimilars containing antibodies, which accounted for 52
out of 65 (80%) of publications for (intended) biosimilars containing
glycoproteins.
Most of the QAs were more frequently reported over time when
comparing the periods 2009–2011 and 2015–2019—from 50% to 79%
for primary structures, 67% to 82% for PTMs, 50% to 63% for HOSs,
and 0% to 47% for immunochemical activity while reporting of some
other QAs slightly decreased over time—from 100% to 71% for purity
and impurities, 100% to 76% for general physicochemical properties,
and 100% to 94% for biological activity—. Interestingly, reporting of
immunochemical activity was first noted in the period 2012-2014
where reporting increased from 27% to 47%, which was in parallel with
the increase of the number of publications and approvals for (intended)
biosimilars of antibodies for which immunochemical activity is relevant
(Table 2).
Of the included 79 publications, 24 (30%) reported all QA types that
are relevant to the active biological substance of (intended) biosimilars
being studied. The number of publications that reported all relevant QA
types increased from 1 (17%) out of 6 publications during 2009-2011
(median= 4.0 QA types) to 21 (34%) out of 62 publications during
Box 1. A constructed classification scheme for the quality attribute types in biosimilarity assessment of biosimilars. * Enzymatic-PTMs and Immunochemical activity
only applies to glycoproteins and antibodies, respectively.
Fig. 1. Flowchart depicting the inclusion criteria of eligible full-text scientific publications.
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2015-2019 (median= 6.0 QA types) (Fig. 2).
3.3. Dynamics of scientific publications of (intended) biosimilars over time
The first scientific publication that presented a biosimilarity as-
sessment of QAs of (intended) biosimilars was published in 2009 while
the first open-access publication was found in 2011. The number of
scientific publications presenting biosimilarity assessments of QAs in-
creased from 6 (7%) publications in the first period 2009–2011 to 11
(14%) publications in the second period 2012–2014 and 62 (79%)
publications in the last period 2015–2019 (Fig. 3).
The first period (2009–2011) included biosimilarity assessments for
(intended) biosimilars containing hormones while more complex (in-
tended) biosimilars containing antibodies became available in latter
periods. These publications presented biosimilarity assessments of QAs
for (intended) biosimilars against reference products for 19 distinctive
active biological substance(s). The number of publications for mono-
clonal antibodies varied and ranged from 1 for tocilizumab to 14 for 18
(intended) biosimilars of rituximab. Most of the hormones were sup-
ported with a single publication, except for 23 filgrastim, 14 epoetin and
3 follitropin alfa (intended) biosimilars, which were supported with 9, 4, 3
publications, respectively (Supplementary Figure-S1).
During the study period, the increase in the number of publications
was in parallel with the increase of regulatory approval of biosimilars
by the EMA and US-FDA (Fig. 3). As of December 2019, the EMA and
US-FDA have approved 46 unique biosimilars with 87 brand names as
alternative to 15 reference products (Supplementary Table-S2). More
than half (56%) of the 46 unique biosimilars have at least one published
biosimilarity assessment of QAs presented in a total of 36 publications
where the majority (n= 33, 92%) was available as open-access pub-
lications. The remaining 43 publications studied (intended) biosimilars
that were not yet approved by EMA and/or US-FDA as of December
2019. The overall average duration of time from the date of regulatory
approval until publishing the first biosimilarity assessment of QAs for
approved biosimilars was twelve months (SD= 27 months). Time from
date of regulatory approval until scientific publication of the first bio-
similarity assessment was the longest for biosimilars containing hor-
mones (average mean= 33 months, SD= 22 months) after approval
and shortest for biosimilars containing antibodies (average mean= 2.5
months, SD= 19 months) before approval (supplementary Figure-
S2).
4. Discussions
Our study found that reporting frequencies of the QA types in bio-
similarity assessments of (intended) biosimilars varied among the in-
cluded scientific publications. The most frequently reported QA types
were the physicochemical properties and biological activity as these
provide first and last insights, respectively, into the (dis)similarity be-
tween the (intended) biosimilar and the reference product at the mo-
lecular level. Reporting of most QA types increased over the study
period, specifically the immunochemical activity that was reported
after the publication of the EMA guidance entitled “guideline on similar
biological medicinal products containing monoclonal antibodies (mAbs)–
non-clinical and clinical issues” in 2012 (EMA, 2012). Although only 26
of the 46 unique biosimilars that have received regulatory approval, as
of December 2019, from the EMA and/or US-FDA have a biosimilarity
assessment of QAs in a scientific publication, the number of publica-
tions has increased over time; furthermore, only one-third of included
publications reported all QA types that are relevant to the active bio-
logical substance of (intended) biosimilars being assessed.
A large variability in the completeness of reporting the QA types
between publications was found, while demonstrating the biosimilarity
would require assessing all QA types that are relevant to the active
Table 1
Baseline characteristics of the included scientific publications.
Baseline characteristics Publications



















Others (e.g., clotting factor and enzyme) 3 (4%)
Table 2
Reporting of quality attribute types in scientific publications on biosimilarity assessments (n = 79), according to date of publication, source of funding, regulatory
status of (intended) biosimilar on the date of publication, and type of therapeutic protein for the (intended) biosimilar.
Total Publication date Funding sources Regulatory status Types of active biological substance
n = 79 2009-2011 2012-2014 2015-2019 Academia Industry Approved Unapproved Antibodies Hormones Others
(%) n = 6 n = 11 n = 62 n = 20 n = 59 n = 30 n = 49 n = 52 n = 24 n = 3
(%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
Structural quality attributes
Physicochemical properties 81 100 100 76 85 80 63 92 77 88 100
Primary structure 77 50 82 79 80 76 63 86 79 75 67
Higher-order structures-HOSs 58 50 36 63 55 59 57 59 56 63 67
Post translation modifications-
PTMs
79 67 64 82 85 76 73 82 79 79 67
Enzymatic PTMs 61 50 46 65 65 59 53 65 75 29 67
Non-Enzymatic PTMs 56 17 55 60 70 51 47 61 54 63 33
Purity and impurities 73 100 73 71 80 71 67 78 67 83 100
Size variants 68 100 73 65 65 70 63 71 62 83 67
Charge variants 57 50 36 61 50 59 57 57 62 46 67
Functional quality attributes
Biological activity 94 100 91 94 95 93 93 94 94 92 100
Immunochemical activity 41 0 27 47 25 46 50 35 62 NA NA
*Enzymatic- PTMs and Immunochemical activity only applies to glycoprotein and antibodies, respectively
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biological substance of an (intended) biosimilar (EMA, 2014; US-
FDA, 2015a). To illustrate this, the enzymatic PTMs (e.g. glycosylation)
and immunochemical activity are specific to (intended) biosimilars
containing glycoproteins and antibodies, respectively, but were not
reported in all pertinent publications. However, the variability in re-
porting QAs is likely to be driven by the relevance of the QA type for the
type of protein. For example, low reporting frequencies of enzymatic-
PTMs in publications of hormones is likely due to the fact that hor-
mones, in most cases, are non-glycoproteins where no existence of
glycosylation precursors exist. The variability in reporting QA types
might also be due to spreading out information on QAs in more than
one publication where a few biosimilars have multiple biosimilarity
assessments of QAs presented in different publications.
The foundation of establishing biosimilarity is the comparability
assessment of QAs between a biosimilars and the reference product,
followed by confirmation of biosimilarity by non-clinical studies,
pharmacokinetics (PK), pharmacodynamics (PD) and comparative
clinical efficacy and safety data where indicated (Wolff-Holz et al.,
2019). The importance of the structural and functional relationship of
QAs in establishing biosimilarity is continuously being better under-
stood and characterized with the advancement in science and analytical
technology. For example, the primary structure is essential in de-
termining HOSs and might influence biological activity
(Kirchhoff et al., 2017). Thus, regulators strictly require an identical
amino acid sequences as a matter of principle because different se-
quence is from a regulatory perspective a different active substance.
Alterations in “correct” folding of protein drugs may affect the receptor
or antigen binding, and likely may hamper the biological and clinical
activity and safety (Berkowitz and Houde, 2014). The PTMs and the
purity and impurity QAs including size and charge variants often play a
role in the biological activity, and such differences can substantially
alter the PK/PD and/or immunogenicity via direct or indirect pathways
(Walsh and Jefferis, 2006). Although differences in certain structural
QAs can influence functional QAs, differences in functional QAs, in-
cluding biological and immunochemical activity-for antibodies only-
might have an impact on clinical parameters such as the serum half-life
or the mode of action(s) (Ghetie et al., 1997; Mori et al., 2007;
Kwon et al., 2017). The evaluation of functional QAs can help to predict
biosimilarity in the clinical performance and adds important knowledge
for extrapolation across therapeutic indications (Weise et al., 2014).
Our data show that publications of unapproved biosimilars focused
more on physiochemical properties and primary structure as these
Fig. 2. The median, minimum, and maximum values of the number of quality attribute types reported in the included publications over time.
Fig. 3. Dynamics of scientific publications presenting biosimilarity assessments of QAs in relation to the year of regulatory approval of biosimilars by EMA and/or
US-FDA.
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structural QA types only provide first insights into the biosimilarity
between two molecules. On the other hand, the publications of ap-
proved biosimilars, which are often mAbs and fusion protein, focused
more on biological and immunochemical activity as these types can link
with the clinical activity and provide final insights into the bosimilarity
at the molecular level. Moreover, the impact of (minor) differences in
structural attributes could be assessed by testing functional attributes
(Eon-Duval et al., 2012; Kwon et al., 2017; Vandekerckhove et al.,
2018) Given the relationships between the QA types and their potential
impact on clinical outcomes, it is important to pay equal attention to all
relevant structural and functional attributes before concluding the
biosimilarity at the quality level. Also, it is essential to report in-
formation on all relevant QAs that have or not met predefined biosi-
milarity criteria. Reporting all QA types relevant to the active biological
substance was found in one-third of publications and seemed to in-
crease over time, showing the willingness of publication-sponsors to
share a comprehensive biosimilarity assessment of QAs.
The number of publications increased considerably during the study
period, although the number is still a marginal fraction of all scientific
publication on biosimilars. This positive trend indicates an improve-
ment in knowledge sharing on biosimilarity assessments of QAs, which
was not identified in previous systematic reviews (Jacobs et al., 2016;
Jacobs et al., 2016; Jacobs et al., 2017). This is perhaps because our
search covered a longer time frame and a wider range of protein types,
and was specifically designed to identify publications reporting biosi-
milarity assessment of QAs and assessed the QAs in more details. The
increase in publications is likely a direct result of the increased devel-
opment of biosimilars following patent expiration of reference biolo-
gicals by the industry and the growing interest in approval of biosi-
milars. The patent expiration of reference biologicals played an
important role in the timing of arrival to markets where the first wave
of approved biosimilars were hormones followed by monoclonal anti-
bodies, the same shifted scope in the protein type of (intended) biosi-
milar was observed in scientific publications over time. The variabilities
in the number of publications between the active biological substances
of (intended) biosimilars (Supplementary Figure-S1) is consistent
with previous findings (Jacobs et al., 2016). The majority of approved
biosimilars (75%) were granted regulatory approval between 2015 and
2019, which is in line with the percentage of publications published
during the study period (2015-2019). Our data also shows that scien-
tific publications presenting biosimilarity assessments of QAs are
available for approximately two-third of the approved biosimilars, re-
vealing a knowledge gap for QAs of some biosimilars in peer reviewed
scientific publications. Although the regulatory process has been shown
to approve biosimilars which are as safe and efficacious as the reference
product, biosimilars still face a sluggish and very low market penetra-
tion and uptake in the US and some European countries
(European Commission, 2019; GaBI, 2019). Disseminating compre-
hensive data on biosimilarity assessment, including the QAs, in the
public domain is necessary for gaining acceptance of biosimilars among
prescribers, payers and patients, thereby achieving sustainable market
uptake.
Our data shows some heterogeneity in publishing on QAs between
publications that are derived from industry or academic institutions,
which is likely explained by the fundamentally different motivations
and expectations related to publishing. The motivation of the industry
is to develop a biosimilar that meets the regulatory requirements, and
as such they always perform a complete assessment of QAs, whereas the
academia’ immediate unit of success is the publications of what they
think is relevant and interesting. The latter might not always include all
QAs as what would be expected for an industry driven biosimilar as-
sessment.
The majority of the included publications were funded by industry
involved in biosimilar development. In addition, open-accessed pub-
lications has increased over time (Supplementary Figure-S3), con-
firming the positive impact of scientific publications about similar
drugs on industry rate of publication about its drug in the public do-
main (Polidoro and Theeke, 2012). This suggests that biosimilar de-
velopers are more willing to share the results of their biosimilarity as-
sessment of QAs through open-access publications with the scientific
and medical community. Transparency in publishing of comprehensive
and unbiased biosimilarity assessment of QA data contributes to better
understanding of the science behind regulatory approval and may in-
creases confidence in biosimilars in medical practice. Academic in-
stitutions sponsored fewer publications in our review when compared
to the industry. This might relate to their limited capacity and resources
e.g., facilities and equipment, although three of the academia sponsored
publications included in our review reported all relevant QA types to
the active biological substance of (intended) biosimilars being assessed.
Other factors that play a role in limiting the academic contribution are
intellectual property rights and inaccessibility to batches of biosimilars
that are not yet marketed (Planinc et al., 2017).
Our data also shows that reporting the QA types over time is likely
influenced by the development of regulatory guidelines of biosimilars
that were published by the EMA and US-FDA during the study period.
This regulatory guidance effect is most evident for reporting of im-
munochemical activity that was not reported in several included pub-
lications of (intended) biosimilars containing antibodies before the
publication of EMA guidance on biosimilars containing monoclonal
antibodies in 2012 (EMA, 2012). The EMA updated guideline entitled
“Similar biological medicinal products containing biotechnology-derived
proteins as active substance: quality issues”, and the US-FDA released a
guideline entitled “quality considerations in demonstrating biosimilarity of
a therapeutic protein product to a reference product” in 2014, and 2015,
respectively (EMA, 2014; US-FDA, 2015a) Although both guidelines,
especially compared to the first version of the EMA quality guideline,
placed more emphasis on all QA types included in the classification
scheme, an increase in reporting was only found for primary structure,
HOSs and PTMs.
Presenting biosimilarity assessment of QAs in scientific publications
is one of several strategies to improve learning in biosimilar develop-
ment, and to maintain communications with the scientific and medical
community. The development of biosimilars together with continuous
advancement in science and analytical technology facilitates the un-
derstanding about the active biological substance by the regulators and
medical community. In the past, reference companies actively stated
that producing biosimilars was almost an impossible task due to
structural and manufacturing process complexity of biological drugs
(Blackstone and Joseph, 2013). Several analytical analyses of different
batches of reference products have shown that there is always some
batch-to-batch variability in QAs as a result of, among others, changes
in the production process (Schiestl et al., 2011; Planinc et al., 2017;
Kim et al., 2017). The availability of a complete assessment of QAs
could result in better understanding of the role of QAs in establishing
biosmilarity and comparability not only for biosimilars at approval time
but also for the reference biologicals as well as biosimilars when
changes in the manufacturing process after the regulatory approval are
introduced. However, among several QAs of biologicals, only a subset
of these are potentially relevant to efficacy, safety, and dosing of a drug,
which are also known as critical quality attributes (CQAs). As such,
CQAs must be routinely monitored and controlled to keep them within
an appropriate limit, range, or distribution to assure the quality of a
biological drug (ICH, 2009). A future challenge is to identify the CQAs
and understand their relation to functional and clinical outcomes. This
might result in a list of CQAs that matter most for establishing the
biosimilarity, which could reshape the current regulatory requirements
of biosimilars by reducing unnecessary comparative clinical trials cur-
rently required for licensing (Wolff-Holz et al., 2019).
To our knowledge, this review is the first study that identifies the
QA types reported in biosimilarity assessments presented in full-text
scientific publications and describes the dynamics of publishing biosi-
milarity assessments and reporting of QA types over time. We
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constructed a classification scheme of QA types, based on regulatory
guidelines and input from regulatory experts, to allow for a uniform
assessment of the included publications. The study also sheds lights on
how many biosimilars that were granted regulatory approval from the
EMA and/or US-FDA have a published biosimilarity assessment of QAs
to support the core evidence of biosimilarity in the literature.
Nevertheless, the present study has several limitations. First, a
quality assessment for the included publications was not undertaken as
there is no tool available to assess the strength/validity of the technical
and analytical studies. Second, QAs might be missed due to hetero-
geneity in how these are defined between scientific publications, as no
official classification system for QAs in biosimilarity assessments exists.
However, we applied a classification scheme co-developed in colla-
boration with regulatory experts thus it is unlikely that QAs were
missed. Third, it cannot be determined whether QAs not reported were
actually not tested or tested but not published by the author(s) because
the present study only relied on published data. Finally, certain pub-
lications might be not included due to different languages or being
unable to pick up in our search strings. However, we developed a search
strategy in which the reference lists of review papers were manually
checked to identify publications potentially missing in the electronic
search, which resulted in an insignificant number of additional pub-
lications relevant to the study objective.
5. Conclusions
We observed a clear increase in the number of scientific publications
that present biosimilarity assessments of QAs for (intended) biosimilars
over time, in line with an increased number of (intended) biosimilars
for antibodies and hormones under development, with a large varia-
bility in the completeness of reporting QAs in these. Publishing of
biosimilarity assessments and reporting of QA types over time appears
to be affected by regulatory actions that occurred in 2012-2015, in-
cluding the regulatory approval and the development of regulatory
guidelines for biosimilars. Availability of a complete, publicly acces-
sible (open access) and unbiased biosimilarity assessment of QAs, as
part of a trusted and transparent regulatory process, will contribute to
increased confidence and acceptance of biosimilars in clinical practice.
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